Table 2.
Primary and Secondary Outcomes
| Baseline (n=90) | Empagliflozin (n=42) | P Value | Placebo (n=36) | P Value | Group difference | P Value | |
|---|---|---|---|---|---|---|---|
| MFR | 2.21 (2.08 to 2.35) | 0.01 (−0.18 to 0.21) | 0.909 | 0.06 (−0.15 to 0.27) | 0.559 | −0.05 (−0.33 to 0.23) | 0.716 |
| MFR, RPP adjusted | 1.97 (1.84 to 2.09) | −0.04 (−0.23 to 0.16) | 0.694 | 0.03 (0.19 to 0.24) | 0.811 | −0.07 (−0.35 to 0.22) | 0.653 |
| Rest flow, mL/g per min | 1.16 (1.08 to 1.24) | −0.10 (−0.16 to −0.02) | 0.011 | −0.15 (−0.23 to −0.08) | >0.001 | 0.06 (−0.03 to 0.15) | 0.176 |
| Stress flow, mL/g per min | 2.45 (2.28 to 2.62) | −0.17 (−0.34 to −0.01) | 0.044 | −0.20 (−0.38 to −0.03) | 0.025 | −0.03 (−0.19 to 0.26) | 0.769 |
| Reversible extent, TPD, % | 4.66 (3.77 to 5.55) | 0.74 (−0.48 to 1.97) | 0.235 | 0.08 (−1.23 to 1.40) | 0.905 | 0.66 (−1.04 to 0.66) | 0.443 |
| HbA1c, % | 7.63 (7.43 to 7.83) | −0.68 (−0.86 to −0.49) | <0.001 | 0.08 (−0−11 to 0.27) | 0.411 | −0.76 (−1.00 to −0.51) | <0.001 |
| HbA1c, mmol/mol | 59.85 (57.66 to 62.04) | −7.40 (−9.39 to −5.42) | 0.86 (−1.21 to 2.95) | −8.27 (−10.94 to −5.60) | |||
| Hematocrit, % | 40.43 (39.62 to 41.24) | 1.36 (0.67 to 2.04) | <0.001 | −0.33 (−1.04 to 0.38) | 0.357 | 1.69 (0.76 to 2.62) | <0.001 |
| eGFR, mL/min per 1.73 m2 | 79.39 (74.63 to 84.16) | −0.71 (−3.90 to 2.74) | 0.660 | 1.25 (−1.94 to 4.43) | 0.440 | −1.96 (−6.29 to 2.37) | 0.373 |
| NT‐proBNP, log‐ng/L | 4.83 (4.57 to 5.11) | −0.25 (−0.53 to 0.03) | 0.077 | −0.12 (−0.40 to 0.16) | 0.412 | −0.12 (−0.52 to 0.26) | 0.506 |
| Weight, kg | 95.01 (91.14 to 98.88) | −0.14 (−2.78 to 1.99) | 0.893 | 0.86 (−1.30 to 3.03) | 0.432 | −1.01 (−4.04 to 2.02) | 0.512 |
| HR, bpm | 69.16 (66.66 to 71.66) | −0.88 (−3.47 to 1.71) | 0.503 | −0.94 (−3.45 to 1.56) | 0.459 | 0.06 (−3.47 to 3.60 | 0.972 |
| Systolic BP, mm Hg | 139.55 (136.18 to 142.92) | −5.55 (−10.59 to −0.51) | 0.031 | −2.93 (−7.57 to 1.71) | 0.213 | −2.62 (−9.28 to 4.05) | 0.439 |
Values are presented as means (95% CI)). BP indicates blood pressure; eGFR, estimated glomerular filtration rate; HR, heart rate; MFR, myocardial flow reserve; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; RPP, rate‐pressure product; and TPD, total perfusion deficit.